^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    DRD3 antagonist

    Related drugs:
    1d
    C-Cog in Early Course Schizophrenia Study (clinicaltrials.gov)
    P4, N=1, Terminated, University of Miami | N=60 --> 1
    Enrollment change
    4d
    Enhancing Recovery in Early Schizophrenia (clinicaltrials.gov)
    P2, N=180, Active, not recruiting, Central Institute of Mental Health, Mannheim | Recruiting --> Active, not recruiting | Trial completion date: Jun 2026 --> Dec 2027 | Trial primary completion date: Jun 2026 --> Dec 2027
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    olanzapine
    8d
    Dexmedetomidine versus Chlorpromazine for Patients in ICU with Hyperactive Delirium: A Single-Center, Prospective, Double-Blind, Randomized Controlled Trial (ChiCTR2500114067)
    P=N/A, N=104, Not yet recruiting, Huashan Hospital Fudan University; Huashan Hospital Fudan University
    New trial
    |
    chlorpromazine
    11d
    NOVA3: 52-week Open Label Safety-Tolerability Study (clinicaltrials.gov)
    P3, N=900, Not yet recruiting, LB Pharmaceuticals Inc.
    New P3 trial
    15d
    NOVA2: Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia (clinicaltrials.gov)
    P3, N=456, Not yet recruiting, LB Pharmaceuticals Inc.
    New P3 trial
    22d
    Characterizing Drug Liking During Drug Administration in Peri-procedural Clinical Settings (clinicaltrials.gov)
    P1, N=100, Not yet recruiting, Stanford University
    New P1 trial
    1m
    ENX-104 MAD Study for Participants With Major Depressive Disorder With Anhedonia (aMDD) (clinicaltrials.gov)
    P1, N=48, Completed, Engrail Therapeutics INC | Recruiting --> Completed
    Trial completion
    2ms
    A PET Study of ENX-104 in Healthy Volunteers (clinicaltrials.gov)
    P1, N=10, Completed, Engrail Therapeutics INC
    New P1 trial
    2ms
    ENX-104 MAD Study for Participants With Major Depressive Disorder With Anhedonia (aMDD) (clinicaltrials.gov)
    P1, N=42, Recruiting, Engrail Therapeutics INC
    New P1 trial
    3ms
    Drug Repurposing Screen Identifies Pimozide as a ROS-Inducing Therapy With Anti-Tumor Efficacy in HNSCC PDX Models. (PubMed, Cancer Sci)
    Notably, pimozide exhibited anti-tumor effects as a monotherapy and in combination with paclitaxel at clinically relevant doses. While tumor volume reduction in the combination group was not statistically greater than that in the monotherapy group, fluorescence immunohistochemistry revealed a marked decrease in undifferentiated tumor cells, indicating enhanced therapeutic effects of combination treatment. Taken together, these findings indicate that pimozide is a promising candidate for repurposing as a novel therapeutic agent against HNSCC.
    Journal
    |
    STAT3 (Signal Transducer And Activator Of Transcription 3) • DRD2 (Dopamine Receptor D2) • EGR1 (Early Growth Response 1)
    |
    paclitaxel
    3ms
    Managing Agitated Delirium With Neuroleptics and Anti-Epileptics as a Neuroleptic Sparing Strategy (clinicaltrials.gov)
    P2/3, N=42, Recruiting, M.D. Anderson Cancer Center | N=30 --> 42
    Enrollment change
    |
    chlorpromazine
    3ms
    Role of Ubiquitin-specific Protease 1 in the Pathogenesis and Treatment of Adult T-Cell Leukemia. (PubMed, Anticancer Res)
    Our study supports the clinical potential of USP1 inhibitors as a novel therapy for ATL.
    Journal
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • LDHA (Lactate dehydrogenase A) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • PLK1 (Polo Like Kinase 1) • USP1 (Ubiquitin Specific Peptidase 1)